A detailed history of Rbf Capital, LLC transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Rbf Capital, LLC holds 45,362 shares of PRTA stock, worth $635,521. This represents 0.04% of its overall portfolio holdings.

Number of Shares
45,362
Previous 45,362 -0.0%
Holding current value
$635,521
Previous $936,000 19.02%
% of portfolio
0.04%
Previous 0.05%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$32.31 - $52.32 $290,790 - $470,880
-9,000 Reduced 16.56%
45,362 $1.65 Million
Q3 2022

Nov 14, 2022

BUY
$25.16 - $60.63 $226,440 - $545,670
9,000 Added 19.84%
54,362 $3.3 Million
Q3 2020

Nov 16, 2020

BUY
$9.93 - $13.47 $351,144 - $476,326
35,362 Added 353.62%
45,362 $453,000
Q3 2020

Nov 16, 2020

SELL
$9.93 - $13.47 $351,144 - $476,326
-35,362 Reduced 77.96%
10,000 $1.23 Million
Q4 2019

Feb 13, 2020

BUY
$7.48 - $17.01 $339,307 - $771,607
45,362 New
45,362 $718,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $657M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Rbf Capital, LLC Portfolio

Follow Rbf Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rbf Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rbf Capital, LLC with notifications on news.